Type approval, which is the requirement for Radio and Telecommunications Terminal Equipment (RTTE) to comply with specific technical standards, is the last thing needed to apply for and receive the remaining approvals which will set the company in position to start commercialization in the country.   

"This approval is another milestone for the Actiste® portfolio in the UAE. We are very pleased that both Actiste® and Actiste® Mini have received type approval for telecom use. We are now focused on completing all the remaining commercialization preparations to bring Brighter's diabetes management platform to patients in need and are optimistic this will happen in line with our time plan", comments Erik Lissner, CEO of Brighter AB.

For further information, please contact:
Investor Relations
ir@brighter.se

Certified Adviser
Brighter's Certified Adviser är Mangold Fondkommission AB,
+46 8 5277 5020, ca@mangold.se,www.mangold.se.

About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is a key to providing smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones, and their care providers - aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter's quality management system is ISO-13485 certified. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.
For more information, please visit our website at https://brighter.se/.